Compositions and methods for enhancing transport through mucus
The invention generally relates to compositions and methods for transporting substances across mucosal barriers. The invention also relates to methods of making and using such substances.
1 . A particle comprising an outer surface and one or more surface-altering moieties disposed on the outer surface that reduce mucoadhesion of the particle, wherein said particle diffuses through human cervicovaginal mucus at a diffusivity that is greater than 1/1000 the diffusivity that the particle diffuses through water at a time scale of 1 s.
2 . A particle comprising an outer surface and one or more surface-altering moieties disposed on the outer surface, whereby the particle moves in human cervicovaginal mucus at a diffusivity of more than 4×10 −2 μm 2 /s at a time scale of 1 s.
3 . A particle comprising an outer surface and one or more surface-altering moieties disposed on the outer surface that reduce mucoadhesion of the particle, wherein the particle has a zeta potential lower than 10 mV.
4 . A particle comprising an outer surface and one or more surface-altering moieties disposed on the outer surface that reduce mucoadhesion of the particle, wherein the mass of the surface-altering moiety makes up at least 1/3400 of the mass of the particle.
5 . A particle comprising an outer surface and one or more surface-altering moieties disposed on the outer surface that reduce mucoadhesion of the particle, wherein the particle adsorbs less than 10% of the amount of fluorescently labeled avidin that is adsorbed by a corresponding particle lacking the surface-altering moiety, as calculated by average maximum fluorescent intensity.
6 . A particle comprising an outer surface and one or more surface-altering moieties disposed on the outer surface that reduce mucoadhesion of the particle, wherein the surface-altering moiety is present on the outer surface at a density of greater than 0.01 units per nanometer squared.
7 - 11 . (canceled)
12 . A particle of claim 1 , wherein the particle comprises a core.
13 . A particle of claim 12 , wherein the core comprises a polymer.
14 . A particle of claim 13 , wherein the polymer comprises surface-altering moieties disposed on the outer surface.
15 . (canceled)
16 . A particle of claim 1 , wherein the particle is a liposome, metal or metal oxide, or a quantum dot.
17 . A particle of claim 1 , wherein one or more bioactive agents are associated with the particle.
18 - 21 . (canceled)
22 . The particle of claim 1 , wherein said particle is larger than 1 nm in diameter.
23 - 25 . (canceled)
26 . The particle of claim 17 , wherein the bioactive agent is an imaging agent or a therapeutic agent.
27 - 29 . (canceled)
30 . The particle of claim 1 , further comprising one or more targeting moieties.
31 . The particle of claim 1 , wherein the one or more surface-altering moieties enhance hydrophilicity of the surface of the particle.
32 - 33 . (canceled)
34 . A pharmaceutical composition comprising the particle of claim 1 and one or more pharmaceutically acceptable carriers.
35 . An inhaler comprising the particle of claim 1 .
36 . A method for treating, preventing, or diagnosing a condition in a patient, comprising administering to the patient one or more particles of claim 1 .
37 - 41 . (canceled)
42 . A composition comprising a plurality of particles, wherein at least 10% of the particles in the composition are particles as defined in claim 1 .
43 - 59 . (canceled)
60 . A method for decreasing the mucoadhesion of a substance, comprising identifying a substance in need of increased diffusivity through mucus, modifying the substance with a surface-altering moiety, and formulating the modified substance in a pharmaceutical preparation suitable for topical administration to a mucosal surface.
61 - 67 . (canceled)
68 . A pharmaceutical preparation suitable for topical administration to a mucus membrane, comprising a bioactive agent associated with a surface-altering moiety.
69 - 73 . (canceled)
74 . An enveloped virus comprising a surface-altering moiety, wherein said virus diffuses through human cervicovaginal mucus at a diffusivity at a time scale of 1 second that is more than 20-fold greater than the diffusivity at which a corresponding virus lacking the surface-altering moiety diffuses through human cervicovaginal mucus.
75 - 76 . (canceled)